@article{TLCR3192,
author = {Fei-Yu Niu and Wen-Zhao Zhong and Qing Zhou and Yi-Long Wu},
title = {Clinical trials for lung cancer in China},
journal = {Translational Lung Cancer Research},
volume = {3},
number = {5},
year = {2014},
keywords = {},
abstract = {Lots of international multi-center clinical trials have been conducted in China over the past 10 years. We also have more and more clinical trials designed and launched by qualified Chinese investigators in recent years, especially after the establishment of the Chinese Thoracic Oncology Group (CTONG) in 2007. These trials are mainly about targeted drugs. The finished ones provided more evidence for the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the first-line/maintenance/second-line settings in Chinese patients. The ongoing ones will diversify the use of EGFR-TKIs in 1st/2nd/3rd line settings and help to answer the questions whether patients will benefit from (neo)adjuvant EGFR-TKIs and chemotherapy intercalating and maintenance use of EGFR-TKIs. Here, we introduce far-reaching clinical trials conducted, ongoing and will be launched soon in China.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/3192}
}